Tularik & Amgen: A Model of Business Development (and Good News for Biotech, Too)

Things have been bleak on the discovery side of the dealmaking world, as evidenced by a paucity of Big Pharma alliances. But the Tularik/Amgen transaction indicates a renewed interest in target-stage transactions, though with the best prospects reserved for cancer focused companies with significant chemistry capabilities.

The prospect of corporate mortality can do wonders to clear the business development mind.

With 18 months to go before its funds ran out, Tularik Inc. did not do the 50-50 deal several...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from In Vivo Archive

More from In Vivo